1st International Harmony SHR® Robotic Rehabilitation System Installed at Prestigious Chinese University of Hong Kong Medical Centre

Harmonic Bionics announced today that the first Harmony SHR® exoskeleton in Hong Kong has been delivered and installed at the Chinese University of Hong Kong (CUHK) Medical Centre to be utilized in the hospital’s rehabilitation program. This marks the very first international placement for Harmonic Bionics and the first in the Hong Kong region with the company’s distributor, Healthlink Holdings.

Harmony SHR is a bilateral upper extremity exoskeleton with a biomechanically matched shoulder designed to allow a larger and more natural arm range of motion for patients recovering from neurological or musculoskeletal impairments. Harmonic Bionics announced the commercial launch of Harmony SHR last April followed by the first US installation at a top neurological hospital in Phoenix.

A high-profile dancer that suffered a spinal cord injury in an accident on stage two years ago was one of the first to use the Harmony SHR exoskeleton at CUHK Medical Centre, under the care of Professor Herman Lau, Director of Allied Health Services, and former Hospital Chief Executive of Shatin Hospital.

“The Harmony SHR exoskeleton is a highly unique robotic device that has been specifically designed for bilateral upper body rehabilitation purposes. The CUHK Medical Centre is proud to announce that it has recently acquired the first Harmony device in Hong Kong,” said Professor Herman Lau. “Patients who have been using the Harmony system have shown remarkable motivation and enthusiasm, which has resulted in some promising outcomes in a relatively short period of time.”

Harmonic Bionics CEO Mark Hunter

“This is a major milestone for our company as we work to expand our footprint and bring Harmony SHR to more providers and patients. There is tremendous opportunity for growth in Asia and this installation at CUHK Medical Centre is a great starting point to our intended success in the market.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version